
Akouos Market Cap | AKUS
As of October 06, 2026 Akouos has a market cap of $ 488 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Akouos
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 184 M | 358 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 358 M | 184 M | 271 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
89bio
ETNB
|
976 M | - | - | $ 1.55 B | ||
|
Syros Pharmaceuticals
SYRS
|
165 M | - | -8.44 % | $ 3.4 M | ||
|
SpringWorks Therapeutics
SWTX
|
4.45 B | - | - | $ 3.48 B | ||
|
Trevena
TRVN
|
5.09 M | - | -46.58 % | $ 31.8 M | ||
|
Oncorus
ONCR
|
8.55 K | - | -8.54 % | $ 3.19 M | ||
|
OncoSec Medical Incorporated
ONCS
|
17.7 M | - | 31.87 % | $ 1.61 M | ||
|
Y-mAbs Therapeutics
YMAB
|
216 M | - | - | $ 382 M | ||
|
Oncternal Therapeutics
ONCT
|
27.3 M | - | -24.12 % | $ 1.56 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
8.96 M | - | -2.99 % | $ 2.47 M | ||
|
Albireo Pharma
ALBO
|
548 M | - | -0.23 % | $ 916 M | ||
|
BELLUS Health
BLU
|
1.7 B | - | - | $ 2.47 B | ||
|
bluebird bio
BLUE
|
3.35 M | - | - | $ 546 M | ||
|
Intra-Cellular Therapies
ITCI
|
13.3 B | - | - | $ 13.6 B | ||
|
CASI Pharmaceuticals
CASI
|
114 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
1.08 M | - | -5.16 % | $ 5.39 M | ||
|
Turning Point Therapeutics
TPTX
|
2.35 B | - | -0.13 % | $ 3.73 B | ||
|
Epizyme
EPZM
|
126 M | - | - | $ 249 M | ||
|
Forward Pharma A/S
FWP
|
584 M | - | -0.75 % | $ 18.7 M | ||
|
Gamida Cell Ltd.
GMDA
|
353 M | - | -18.25 % | $ 5.04 M | ||
|
Regulus Therapeutics
RGLS
|
52.7 M | - | - | $ 155 M | ||
|
Marinus Pharmaceuticals
MRNS
|
497 M | - | - | $ 29.6 M | ||
|
NeuBase Therapeutics
NBSE
|
6.27 M | - | -1.56 % | $ 12.3 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
3.8 M | - | -48.37 % | $ 3.71 M | ||
|
scPharmaceuticals
SCPH
|
210 M | - | - | $ 218 M | ||
|
Athersys
ATHX
|
8.07 M | - | 3.77 % | $ 22.4 M | ||
|
Seagen
SGEN
|
26.3 B | - | - | $ 42.2 B | ||
|
Sigilon Therapeutics
SGTX
|
39.9 M | - | - | $ 728 M | ||
|
Rubius Therapeutics
RUBY
|
11.7 M | - | -33.55 % | $ 7.81 M | ||
|
TRACON Pharmaceuticals
TCON
|
5.89 M | - | -1.38 % | $ 46.8 M | ||
|
Revance Therapeutics
RVNC
|
479 M | - | - | $ 309 M | ||
|
Sierra Oncology
SRRA
|
288 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
2.96 M | - | -61.37 % | $ 654 K | ||
|
Forma Therapeutics Holdings
FMTX
|
467 M | - | - | $ 958 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
Blueprint Medicines Corporation
BPMC
|
5.96 B | - | - | $ 8.14 B | ||
|
Paratek Pharmaceuticals
PRTK
|
81 M | - | - | $ 121 M | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | ||
|
Nabriva Therapeutics plc
NBRV
|
4.1 M | - | - | $ 4.55 M | ||
|
NGM Biopharmaceuticals
NGM
|
127 M | - | - | $ 127 M | ||
|
Unity Biotechnology
UBX
|
28.1 M | - | -33.41 % | $ 3.37 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Titan Pharmaceuticals
TTNP
|
5.23 M | - | -3.76 % | $ 3.47 M | ||
|
iTeos Therapeutics
ITOS
|
293 M | - | - | $ 411 M | ||
|
Allena Pharmaceuticals
ALNA
|
26 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
TCR2 Therapeutics
TCRR
|
57.9 M | - | - | $ 58.1 M | ||
|
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B |